中文

公司新聞

當前位置: 首頁 > 新聞動態 > 公司新聞

領晟醫療任命Matthias Straub博士為首席醫學官

2020-06-15


Link Health Appoints Chief Medical Officer


Guangzhou, China; 15 June 2020 - Link Health Pharma Co., Ltd. (“Link Health”) announced today it has appointed Dr. Matthias Straub as Chief Medical Officer.


Matthias Straub, MD, PhD, is a recognized pharmaceutical industry  leader and multidisciplinary expert. He has more than 29 years of experience in Clinical Development at big pharma companies such as Ciba Geigy, Solvay Pharmaceuticals, and Abbott Established Pharmaceuticals.


As head of Global Clinical Developmet at major pharma companies, Dr. Straub has built and guided various clinical development departments with a track record in the design and conduct of clinical studies in all development phases and various therapeutic areas. For over 14 years he was responsible  for the final review of all clinical output regarding clinical development of the companies he served. He acted hands on as the responsible Global Clinical Director and Clinical Development Expert, including FDA Advisory Panel meetings, EMA, MHRA, and NMPA hearings for product approvals.


Dr. Straub is a Registered Physician in Germany and has received a Doctors degree in Ophthalmology. He has published on various areas such as congestive heart failure, arrhythmias, and angina pectoris. He holds various patents primarily in the cardiovascular field and was part of the EFPIA efficacy working party for Solvay Pharmaceuticals.


“Dr. Straub is a veterian in our industry. We are very pleased to have him on board to boost the clinical development of our pipeline. His extensive clinical development leadership experience and his hands on approach will definitely benefit us in establishing a world class medical organisation.” Said Yan Song, CEO of Link Health.


About Link Health


Link Health is a biopharmaceutical company developing innovative medicine for unmet medical needs. It has a drug development pipeline of 5 clinical stage assets and 1 under NDA reviewing in China. Headquartered in China, Link Health has an European office in the Netherlands to further strengthen the collaborations with global biopharmaceutical 


2020年06月15日,廣州。領晟醫療科技有限公司正式任命Matthias Straub博士為公司首席醫學官。Straub博士將全面參與領晟在研的多個創新靶點的臨床POC研究,支持領晟的國際合作以及海外申報,同時,Straub博士也將支持領晟自主開發的骨科DMOAD藥物為主的“骨新生”板塊,計劃年內申報美國FDA并計劃同步開展II期臨床研究。


Matthias Straub(MD,PhD)是醫藥界公認的意見領袖和多學科專家,作為一位的資深行業領導者,Matthias Straub博士在臨床開發領域擁有超過29年工作經驗,先后任職Ciba Geigy,蘇威制藥和雅培等跨國企業。

 

Straub博士作為全球臨床開發負責人,多次指導臨床開發各階段和眾多治療領域的臨床研究設計和開展并獲得成功,在過去的14年中,他對所服務公司的臨床發展進行了臨床結果的最終審查,并親自擔任臨床總監、臨床開發專家參與到FDA咨詢小組會議、EMA、MHRA、NMPA聽證會,直至產品獲得批準。

 

Straub博士是德國的注冊醫師,獲得眼科博士學位,他在充血性心力衰竭、心律不齊和心絞痛等疾病領域曾發表文章,在心血管領域擁有多項專利,并曾作為蘇威制藥EFPIA(歐盟制藥工業聯合研發委員會)工作組成員,致力于研究、開發和生產新的醫療方法。

 

領晟醫療CEO宋燕博士表示:“Straub博士是行業的資深人士,我們很高興能邀請他加入我們,一起推動領晟臨床研發管線,他豐富的臨床開發領導經驗和實踐經驗,必將使我們在成為世界一流醫藥企業的路上收益匪淺?!?

 

關于領晟

領晟醫療是一家生物制藥公司,致力于開發國內未滿足的臨床需求的創新藥物。它在中國的研發管線包括了5個臨床階段的創新藥和1個正在接受NDA審查的藥物。領晟醫療總部位于中國,并在荷蘭設有歐洲辦事處,以便公司加強與全球生物制藥公司和研究機構的進一步合作。

 

合作聯系

更多項目信息或公司信息,請聯系:

王華   博士

h.wang@healthinlink.com




国产一级A片免费观看不用下载